SARS-CoV-2 FP vaccine / University of Virginia - LARVOL DELTA

[VIRTUAL] A new, globally appropriate rapid vaccine production platform: killed whole cell genome-reduced bacterial vaccine with surface-expressed antigen: applications to coronavirus and HIV fusion peptides (IAS-HIV 2021) - "The 4 adjacent residues upstream and the 3 residues downstream to the core are identical between SARS-CoV-2 and PEDV. We tested PEDV FP and SARS-CoV-2 FP vaccines (IM) in a PEDV pig model... The genome-reduced bacterial surface-expressed vaccine platform has potential utility as an inexpensive, readily manufactured, and rapid vaccine platform for other pathogens. We are applying the technology HIV vaccines."

Clinical • Human Immunodeficiency Virus • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Killed whole-genome reduced-bacteria surface-expressed coronavirus fusion peptide vaccines protect against disease in a porcine model. (PubMed, Proc Natl Acad Sci U S A) - "Since SARS-CoV-2 FP and PEDV FP vaccines provided similar clinical protection, the coronavirus FP could be a target for a broadly protective vaccine using any platform. Importantly, the genome-reduced bacterial surface-expressed vaccine platform, when using a vaccine-appropriate bacterial vector, has potential utility as an inexpensive, readily manufactured, and rapid vaccine platform for other pathogens."

Journal • Preclinical • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

[VIRTUAL] SARS-CoV-2 full length spike protein for COVID-19 vaccine development and diagnostic testing (AAAAI 2021) - "The purified spike protein did not react with COVID-19 negative patient sera and had high reactivity to COVID-19 positive patients . The pure and immunoreactive spike protein has applications in antibody testing and vaccine development."

Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Convalescent Plasma for Treatment of COVID-19 Patients With Pneumonia (clinicaltrials.gov) - P2; N=29; Recruiting; Sponsor: University of Virginia; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open

Convalescent Plasma for Treatment of COVID-19 Patients With Pneumonia (clinicaltrials.gov) - P2; N=29; Not yet recruiting; Sponsor: University of Virginia

Clinical • New P2 trial

Clinical Validation of New Injection Molded Flocked Nasopharyngeal Swabs in Response to the COVID-19 Pandemic (clinicaltrials.gov) - P=N/A; N=40; Recruiting; Sponsor: University of Virginia

Clinical • New trial • Infectious Disease • Novel Coronavirus Disease